From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial-Reference-Cited by-同舟云学术

From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial

Published:2023-08 Issue: Volume:185 Page:109713
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

De Cock Lisa,Draulans Cédric,Pos Floris J.,Isebaert Sofie,De Roover Robin,van der Heide Uulke A.,Smeenk Robert J.,Kunze-Busch Martina,van der Voort van Zyp Jochem,de Boer Hans,Kerkmeijer Linda G.W.,Haustermans Karin

Funder

Kom op tegen kanker

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference27 articles.

1. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial;Kerkmeijer;J Clin Oncol,2021

2. Hypofractionation in Prostate Cancer: How Far Can We Go?;Hoskin;Clin Oncol,2008

3. Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial;Dearnaley;J Clin Oncol,2020

4. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer;Catton;J Clin Oncol,2017

5. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial;Incrocci;Lancet Oncol,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-09

2. Instant Oncology: FLAME;Clinical Oncology;2024-05

3. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial;Clinical and Translational Radiation Oncology;2024-05

4. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial;Radiotherapy and Oncology;2024-04

5. Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review;World Journal of Urology;2024-01-20